TY - JOUR
T1 - Current perspectives on the treatment of patients with chronic myeloid leukemia
T2 - An individualized approach to treatment
AU - Jabbour, Elias
AU - Cortes, Jorge
AU - Giles, Francis
AU - Kantarjian, Hagop
PY - 2007/11
Y1 - 2007/11
N2 - Purpose: The BCR-ABL tyrosine kinase inhibitor imatinib has dramatically improved the prognosis for most patients with chronic myeloid leukemia (CML). Efforts to optimize therapy in CML have resulted in new and revised treatment guidelines or algorithms, which are reviewed here. Methods: Data were identified by searches of MEDLINE, PubMed, and references from relevant articles using the terms "chronic myeloid leukemia, " "imatinib" and "tyrosine kinase inhibitors. " Articles published in English between 1996 and 2006 were included. Results: In this article we review consensus criteria for a therapeutic response and current expectations for CML therapy with imatinib, as well as the evidence supporting these recommendations. In addition, novel approaches to CML treatment are considered in light of the availability of second-generation tyrosine kinase inhibitors. Conclusion: With the advent of novel agents capable of treating imatinib-resistant or imatinib-intolerant CML, it should be possible in the future to further refine treatment algorithms.
AB - Purpose: The BCR-ABL tyrosine kinase inhibitor imatinib has dramatically improved the prognosis for most patients with chronic myeloid leukemia (CML). Efforts to optimize therapy in CML have resulted in new and revised treatment guidelines or algorithms, which are reviewed here. Methods: Data were identified by searches of MEDLINE, PubMed, and references from relevant articles using the terms "chronic myeloid leukemia, " "imatinib" and "tyrosine kinase inhibitors. " Articles published in English between 1996 and 2006 were included. Results: In this article we review consensus criteria for a therapeutic response and current expectations for CML therapy with imatinib, as well as the evidence supporting these recommendations. In addition, novel approaches to CML treatment are considered in light of the availability of second-generation tyrosine kinase inhibitors. Conclusion: With the advent of novel agents capable of treating imatinib-resistant or imatinib-intolerant CML, it should be possible in the future to further refine treatment algorithms.
KW - Chronic myeloid leukemia
KW - Imatinib
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=39749197458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39749197458&partnerID=8YFLogxK
U2 - 10.1097/PPO.0b013e31815b0df7
DO - 10.1097/PPO.0b013e31815b0df7
M3 - Article
C2 - 18032972
AN - SCOPUS:39749197458
SN - 1528-9117
VL - 13
SP - 357
EP - 365
JO - Cancer Journal
JF - Cancer Journal
IS - 6
ER -
